ArticleThe Saudi dental journal2026
Salivary glutathione versus selenium as an oral cancer risk biomarker: A case-control study.
Article in The Saudi dental journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral squamous cell carcinoma (OSCC) is the most common oral cancer worldwide, with a high mortality that is associated with a delay in diagnosis, especially in areas with poorly developed health infrastructure. The purpose of this study is to determine if salivary glutathione and selenium levels are significantly different between oral cancer patients and healthy subjects. Levels of salivary glutathione, a biomarker of oxidative stress seen in oral cancer and selenium, which augments its function, were compared in healthy low-risk (control), healthy high-risk and oral cancer patients. A reduced level of glutathione was found in oral cancer cases (5.047 ± 0.5115 µM) compared to healthy high-risk patients (5.273 ± 0.3240 µM) and healthy low-risk control subjects (5.618 ± 0.5213 µM), while salivary selenium levels were elevated in oral cancer and healthy high-risk groups compared to healthy low-risk controls. Salivary glutathione level could be a predictor of risk of oral cancer and as a marker for assessment of the effectiveness of management of oral cancer cases, towards improved patient care.
Indexed as
Identifiers
41882480What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.